Entries by aaron

NIRF 2025 Rankings: Jamia Hamdard Leads Pharmacy Institutes, Pan-India Colleges in Top 10

New Delhi: The Ministry of Education has released the latest National Institutional Ranking Framework (NIRF) 2025 for pharmacy institutions, with Jamia Hamdard, New Delhi, once again emerging as the country’s top-ranked institute in the field. The NIRF Ranking 2025 highlights the standard of teaching, research, infrastructure, innovation, and perception in these institutions. The rankings were […]

Indian Pharma Market Grows 8.7% in August, Records Rs 20,984 Crore Sales: PharmaTrac

New Delhi: The Indian Pharmaceutical Market (IPM) grew 8.7% in August 2025, reaching Rs 20,984 crore in value, according to the latest PharmaTrac Industry Report by Pharmarack. In unit terms, the market expanded by 1.2%, underscoring steady demand despite volume stagnation. Growth in August was largely price-driven, supported by new product launches and seasonal therapies. […]

WBMCC notifies on guidelines for AYUSH admissions 2025, check details

West Bengal- The Government of West Bengal has issued a notice for the National Eligibility and Entrance Test-Undergraduate (NEET UG) Ayush 2025 Counselling in West Bengal for Under Graduate AYUSH State Quota, AYUSH Private College Management Quota and AYUSH Private College Central Quota seats 2025. The candidates who have qualified through NEET UG 2025 conducted […]

Exploring Buccal Prochlorperazine: A Targeted Review of Its Pharmacological Profile

The Clinical Value of Buccal Prochlorperazine Prochlorperazine remains a clinically valuable agent for managing nausea, dizziness, vertigo, and vestibular migraine. (1) However, oral administration is often limited by variable absorption, significant first-pass metabolism, and poor tolerability in symptomatic patients. With such clinical needs, buccal delivery serves as a relevant treatment option with potential advantages in […]

Chhattisgarh signs MoU for 240-bed super specialty hospital in Bastar

Raipur: The Chhattisgarh government on Wednesday signed a memorandum of understanding (MoU) with a Telangana-based hospital for operating a 240-bed super speciality hospital, built at a cost of Rs 200 crore in Jagdalpur, the headquarters of Bastar district in the state, an official said. Chhattisgarh’s Department of Medical Education and Continental Hospitals, Telangana, signed the MoU […]

Monoclonal Antibodies Drive Pathogenesis in Heparin-Induced Thrombocytopenia: NEJM

Heparin-induced thrombocytopenia (HIT) is a serious immune-mediated adverse effect of heparin therapy, characterised by thrombocytopenia and a high risk of thrombotic complications. Despite established clinical and laboratory diagnostic criteria, the precise immunopathogenesis of HIT remains incompletely understood. The identification of specific pathogenic antibodies could provide insights into disease mechanisms and guide the development of targeted […]

Early Metabolic Patterns in Prediabetes Help Predict Long-Term Complications: Study

A new long-term study published in the journal of Diabetes Care revealed that early metabolic patterns in prediabetes can forecast the risk of developing severe complications decades later in individuals at risk of type 2 diabetes (T2D). The findings highlight that while many people with prediabetes remain metabolically stable, specific subgroups face sharply increased risks of […]

FFR-Guided Complete Revascularization Beneficial in NSTEMI With Multivessel Disease: JAMA

Netherlands: Researchers have found in a new study that fractional flow reserve–guided complete revascularization during the index procedure is effective for patients with non–ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease. The trial, published in JAMA and led by Dr. Tobias F.S. Pustjens from the Department of Cardiology at Zuyderland Medical Centre, the Netherlands, provides […]

Baricitinib not linked to increased VTE Risk in Alopecia Areata Patients: Study

A new study published in the International Journal of Dermatology revealed that alopecia areata patients treated with baricitinib had no reported thrombotic events over 6 months, indicating no increased risk of venous thromboembolism (VTE) in this population. Based on post-marketing data from patients with rheumatoid arthritis (RA) receiving tofacitinib, the European Medicines Agency (EMA) released […]